TIFFANY LACK: Open Payments
NPI 1700431723 · MAUMELLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,028 in 48 payments from 13 companies in 2025. Trend: 2023 $350 · 2024 $924 · 2025 $1,028
Food & beverage: $1,028
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $284 |
| Axsome Therapeutics, Inc. | 9 | $194 |
| Supernus Pharmaceuticals, Inc. | 11 | $145 |
| Eisai Inc. | 1 | $124 |
| SANOFI-AVENTIS U.S. LLC | 2 | $93 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Lundbeck LLC | 2 | $31 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $26 |
| SHIELD THERAPEUTICS INC | 1 | $25 |
| Organon LLC | 1 | $19 |
Products named: VRAYLAR, Auvelity, Qelbree, Leqembi, TZIELD, AIRSUPRA, VYEPTI, CAPLYTA.
Industry payments across AR — which companies pay providers there.
